Effect of fragile histidine triad gene transduction on proliferation and apoptosis of human hepatocellular carcinoma cells

World Journal of Gastroenterology

Volumn 14, Issue 23, 2008, Pages 3754-3758

  Xu, Rong Hua ^a   Zheng, Liang Yan ^a   He, Dong Lei ^a   Tong, Jian ^a   Zheng, Li Ping ^a   Zheng, Wu Ping ^a   Meng, Jin ^a   Xia, Li Ping ^a   Wang, Cong Jun ^b   Yi, Ji Lin ^c  

^a HAINAN MEDICAL UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Fragile histidine triad gene; Gene therapy; Hepatocellular carcinoma

Indexed keywords

FRAGILE HISTIDINE TRIAD PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CONTROLLED STUDY; GENE CONSTRUCT; GENE EXPRESSION; GROWTH RATE; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RECOMBINANT GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR VOLUME; WESTERN BLOTTING;

EID: 54349112398     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.3754     Document Type: Article

References (30)

1. Ohta M, Inoue H, Cotticelli MG, Kastury K, Baffa R, Palazzo J, Siprashvili Z, Mori M, McCue P, Druck T, Croce CM, Huebner K. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell 1996; 84: 587-597
2. Sozzi G, Veronese ML, Negrini M, Baffa R, Cotticelli MG, Inoue H, Tornielli S, Pilotti S, De Gregorio L, Pastorino U, Pierotti MA, Ohta M, Huebner K, Croce CM. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell 1996; 85: 17-26
3. Negrini M, Monaco C, Vorechovsky I, Ohta M, Druck T, Baffa R, Huebner K, Croce CM. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res 1996; 56: 3173-3179
4. Virgilio L, Shuster M, Gollin SM, Veronese ML, Ohta M, Huebner K, Croce CM. FHIT gene alterations in head and neck squamous cell carcinomas. Proc Natl Acad Sci USA 1996; 93: 9770-9775
5. Sozzi G, Pastorino U, Moiraghi L, Tagliabue E, Pezzella F, Ghirelli C, Tornielli S, Sard L, Huebner K, Pierotti MA, Croce CM, Pilotti S. Loss of FHIT function in lung cancer and preinvasive bronchial lesions. Cancer Res 1998; 58: 5032-5037
6. Campiglio M, Pekarsky Y, Menard S, Tagliabue E, Pilotti S, Croce CM. FHIT loss of function in human primary breast cancer correlates with advanced stage of the disease. Cancer Res 1999; 59: 3866-3869
7. Sorio C, Baron A, Orlandini S, Zamboni G, Pederzoli P, Huebner K, Scarpa A. The FHIT gene is expressed in pancreatic ductular cells and is altered in pancreatic cancers. Cancer Res 1999; 59: 1308-1314
8. Birrer MJ, Hendricks D, Farley J, Sundborg MJ, Bonome T, Walts MJ, Geradts J. Abnormal Fhit expression in malignant and premalignant lesions of the cervix. Cancer Res 1999; 59: 5270-5274
9. Thiagalingam S, Lisitsyn NA, Hamaguchi M, Wigler MH, Willson JK, Markowitz SD, Leach FS, Kinzler KW, Vogelstein B. Evaluation of the FHIT gene in colorectal cancers. Cancer Res 1996; 56: 2936-2939
10. Huebner K, Croce CM. Cancer and the FRA3B/FHIT fragile locus: it's a HIT. Br J Cancer 2003; 88: 1501-1506
11. Yuan BZ, Keck-Waggoner C, Zimonjic DB, Thorgeirsson SS, Popescu NC. Alterations of the FHIT gene in human hepatocellular carcinoma. Cancer Res 2000; 60: 1049-1053
12. Barnes LD, Garrison PN, Siprashvili Z, Guranowski A, Robinson AK, Ingram SW, Croce CM, Ohta M, Huebner K. Fhit, a putative tumor suppressor in humans, is a dinucleoside 5′,5‴-P1,P3-triphosphate hydrolase. Biochemistry 1996; 35: 11529-11535
13. Gramantieri L, Chieco P, Di Tomaso M, Masi L, Piscaglia F, Brillanti S, Gaiani S, Valgimigli M, Mazziotti A, Bolondi L. Aberrant fragile histidine triad gene transcripts in primary hepatocellular carcinoma and liver cirrhosis. Clin Cancer Res 1999; 5: 3468-3475.
14. Zochbauer-Muller S, Wistuba II, Minna JD, Gazdar AF. Fragile histidine triad (FHIT) gene abnormalities in lung cancer. Clin Lung Cancer 2000; 2: 141-145
15. Ishii H, Ozawa K, Furukawa Y. Alteration of the fragile histidine triad gene early in carcinogenesis: an update. J Exp Ther Oncol 2003; 3: 291-296
16. Guler G, Uner A, Guler N, Han SY, Iliopoulos D, McCue P, Huebner K. Concordant loss of fragile gene expression early in breast cancer development. Pathol Int 2005; 55: 471-478
17. Weiske J, Albring KF, Huber O. The tumor suppressor Fhit acts as a repressor of beta-catenin transcriptional activity. Proc Natl Acad Sci USA 2007; 104: 20344-20349
18. Ishii H, Furukawa Y. Alterations of common chromosome fragile sites in hematopoietic malignancies. Int J Hematol 2004; 79: 238-242
19. Lee SH, Kim HY, Kim TJ, Park HK, Kim WH, Woo KM, Cho MH. Aberrant splicing of FHIT transcripts in human gastric cancer cell lines. Res Commun Mol Pathol Pharmacol 2002; 112: 39-49
20. McAvoy S, Ganapathiraju SC, Ducharme-Smith AL, Pritchett JR, Kosari F, Perez DS, Zhu Y, James CD, Smith DI. Non-random inactivation of large common fragile site genes in different cancers. Cytogenet Genome Res 2007; 118: 260-269
21. Smith DI, McAvoy S, Zhu Y, Perez DS. Large common fragile site genes and cancer. Semin Cancer Biol 2007; 17: 31-41
22. Iliopoulos D, Guler G, Han SY, Druck T, Ottey M, McCorkell KA, Huebner K. Roles of FHIT and WWOX fragile genes in cancer. Cancer Lett 2006; 232: 27-36
23. Zawacka-Pankau J, Podhajska AJ. Expression and simple, one-step purification of fragile histidine triad (Fhit) tumor suppressor mutant forms in Escherichia coli and their interaction with protoporphyrin IX. Biotechnol Lett 2007; 29: 877-883
24. Huang K, Frey PA. Engineering human Fhit, a diadenosine triphosphate hydrolase, into an efficient dinucleoside polyphosphate synthase. J Am Chem Soc 2004; 126: 9548-9549
25. Tsujiuchi T, Sasaki Y, Oka Y, Konishi Y, Tsutsumi M. Fhit gene alterations in hepatocarcinogenesis induced by a choline-deficient L-amino acid-defined diet in rats. Mol Carcinog 2003; 36: 147-152
26. Golebiowski F, Kowara R, Pawelczyk T. Distribution of Fhit protein in rat tissues and its intracellular localization. Mol Cell Biochem 2001; 226: 49-55
27. Tsujiuchi T, Sasaki Y, Kubozoe T, Tsutsumi M, Konishi Y, Nakae D. Alterations of the Fhit gene in hepatocellular carcinomas induced by N-nitrosodiethylamine in rats. Mol Carcinog 2002; 34: 19-24
28. Asensio AC, Rodriguez-Ferrer CR, Oaknin S, Rotllan P. Biochemical and immunochemical characterisation of human diadenosine triphosphatase provides evidence for its identification with the tumour suppressor Fhit protein. Biochimie 2006; 88: 461-471
29. Han SY, Iliopoulos D, Druck T, Guler G, Grubbs CJ, Pereira M, Zhang Z, You M, Lubet RA, Fong LY, Huebner K. CpG methylation in the Fhit regulatory region: relation to Fhit expression in murine tumors. Oncogene 2004; 23: 3990-3998
30. Siprashvili Z, Sozzi G, Barnes LD, McCue P, Robinson AK, Eryomin V, Sard L, Tagliabue E, Greco A, Fusetti L, Schwartz G, Pierotti MA, Croce CM, Huebner K. Replacement of Fhit in cancer cells suppresses tumorigenicity. Proc Natl Acad Sci USA 1997; 94: 13771-13776